Neha  Krishnamohan net worth and biography

Neha Krishnamohan Biography and Net Worth

Neha brings over 12 years of experience in healthcare investment banking and finance. Neha joined us from Goldman Sachs where she most recently served as a vice president in the Healthcare Investment Banking Group and a member of the Mergers and Acquisitions (M&A) Group within the Investment Banking Division. While at Goldman Sachs, she established herself as a senior leader in the healthcare coverage group, working with a variety of biopharmaceutical boards and management teams on a broad range of strategic financial matters, executing financings as well as leading M&A transactions. Neha has successfully executed over $100 billion in transactions in the biopharmaceutical, medical technology, and tools/diagnostics sectors. She holds a BSE in Biomedical Engineering and Economics from Duke University.

How old is Neha Krishnamohan?

Ms. Krishnamohan is currently 36 years old. There are 3 older executives and no younger executives at Kinnate Biopharma. The oldest executive at Kinnate Biopharma is Dr. Richard Thomas Williams MBBS, Ph.D., Chief Medical Officer, who is 55 years old. Learn More on Neha Krishnamohan's age.

How do I contact Neha Krishnamohan?

The corporate mailing address for Ms. Krishnamohan and other Kinnate Biopharma executives is , , . Kinnate Biopharma can also be reached via phone at 858-299-4699 and via email at [email protected]. Learn More on Neha Krishnamohan's contact information.

Has Neha Krishnamohan been buying or selling shares of Kinnate Biopharma?

Neha Krishnamohan has not been actively trading shares of Kinnate Biopharma during the past quarter. Learn More on Neha Krishnamohan's trading history.

Who are Kinnate Biopharma's active insiders?

Kinnate Biopharma's insider roster includes Nima . (Pres), Carl Gordon (Director), Neha Krishnamohan (CFO), and Mark Meltz (COO). Learn More on Kinnate Biopharma's active insiders.

Are insiders buying or selling shares of Kinnate Biopharma?

In the last year, Kinnate Biopharma insiders bought shares 4 times. They purchased a total of 3,326,815 shares worth more than $9,074,491.04. The most recent insider tranaction occured on May, 8th when Director James B Tananbaum bought 1,780,000 shares worth more than $4,984,000.00. Insiders at Kinnate Biopharma own 41.7% of the company. Learn More about insider trades at Kinnate Biopharma.

Information on this page was last updated on 5/8/2023.

Neha Krishnamohan Insider Trading History at Kinnate Biopharma

See Full Table

Neha Krishnamohan Buying and Selling Activity at Kinnate Biopharma

This chart shows Ms. Neha Krishnamohan's buying and selling at Kinnate Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kinnate Biopharma Company Overview

Kinnate Biopharma logo
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Read More

Today's Range

Now: $2.67
Low: $2.66
High: $2.69

50 Day Range

MA: $2.47
Low: $2.24
High: $2.66

2 Week Range

Now: $2.67
Low: $1.04
High: $7.18

Volume

81,092 shs

Average Volume

364,936 shs

Market Capitalization

$125.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36